HGH Fragment 176-191 Preclinical

What It Is

HGH Fragment 176-191 is a synthetic peptide corresponding to the carboxy-terminal region of the 22 kilodalton isoform of human growth hormone — specifically amino acid residues 176 through 191. The fragment was identified during structure-activity work in the late 1980s and 1990s aimed at dissecting which region of the 191-amino-acid GH molecule was responsible for its lipolytic (fat-mobilizing) effect, versus the regions responsible for its growth-promoting (IGF-1-mediated) and diabetogenic (insulin-resistance-inducing) effects.

Frank Ng and colleagues at Monash University published the seminal C-terminal GH fragment research in the 1980s–1990s, demonstrating that the lipolytic activity of GH could be localized to the C-terminal domain and was structurally and functionally separable from the central helical domain responsible for GH-receptor binding. The 176–191 fragment recapitulated GH's lipolytic effects in rodent adipocyte cultures and in animal models of obesity, without producing the hyperglycemia, insulin resistance, IGF-1 elevation, or tissue growth that characterize full-length GH.

Metabolic Pharmaceuticals (Australia) developed a commercial analog, AOD-9604 (Anti-Obesity Drug 9604), which is HGH Fragment 176-191 with an additional N-terminal tyrosine residue (Tyr-hGH177-191) added to improve pharmaceutical stability. AOD-9604 entered formal clinical development for obesity in the early 2000s, progressed through Phase I and Phase II trials, and ultimately failed to meet registrational weight-loss endpoints in adequately powered Phase IIb studies. The obesity clinical development program was terminated in 2007. AOD-9604 was subsequently marketed in Australia as a food-supplement ingredient under the TGA's listed-medicine framework rather than as a therapeutic drug.

The parent compound HGH Fragment 176-191 itself has never been advanced into a formal human clinical development program. Its community use and compounding-pharmacy-era protocols for fat loss were built on mechanistic inference from preclinical literature and extrapolation from AOD-9604's short-term lipolytic data — not from direct controlled human efficacy trials of the parent fragment. It is now a Category 2 bulk drug substance in the United States and is not eligible for 503A / 503B compounding.

The structural rationale for the fragment is worth unpacking. The 191-amino-acid full-length GH molecule has multiple functional domains: a central four-alpha-helix bundle responsible for GH receptor binding (residues roughly 1–130), and a C-terminal region (residues ~150–191) involved in lipid metabolism effects. Classical structure-activity work going back to the 1970s established that proteolytic cleavage of GH could separate its lipolytic activity from its growth-promoting / diabetogenic activity, and the Ng laboratory's work identified residues 176–191 as the minimum sequence preserving meaningful lipolytic potency. The fragment does not retain the three-dimensional folded structure of intact GH; it is a short linear peptide whose biological activity depends on a different receptor system than GH itself uses.

The practical implication: HGH Fragment 176-191 is not a growth-hormone analog in the pharmacological sense. It does not replace any function of GH for GH-deficient patients. It does not elevate IGF-1. It does not drive tissue growth, recovery, or sleep-architecture changes. Anyone expecting "GH effects without GH side effects" from the fragment is mis-framing what the fragment is — it is a selective lipolytic peptide whose utility, if any, is narrow to the fat-loss hypothesis.

Mechanism of Action

HGH Fragment 176-191 acts on adipocytes through mechanisms that partially overlap with full-length GH's lipolytic activity but diverge from GH's growth-promoting and glucose-disrupting effects.

• Lipolysis stimulation (beta-adrenergic pathway interaction) — Rodent adipocyte work (Heffernan et al., Endocrinology 2001; PMID 11713212) demonstrated that the fragment increases hormone-sensitive lipase activity and adipocyte triglyceride breakdown, with evidence of beta-3 adrenergic pathway involvement. The net effect is increased free fatty acid release from adipose tissue.
• Lipogenesis inhibition — Downregulates expression and activity of lipogenic enzymes including fatty acid synthase and acetyl-CoA carboxylase in rodent adipocytes, reducing the conversion of dietary substrates into new triglyceride stores.
• No engagement of the classical GH receptor (GHR) — The fragment does not bind the GH receptor with meaningful affinity. Accordingly, it does not activate JAK2/STAT5 signaling, does not stimulate hepatic IGF-1 production, and does not drive tissue growth or the somatogenic effects of full-length GH. This is the central mechanistic distinction that underpins the compound's therapeutic hypothesis.
• No insulin-antagonism effects — Full-length GH is diabetogenic — it opposes insulin action in liver and muscle, producing glucose intolerance at pharmacologic doses. The C-terminal fragment lacks the structural determinants responsible for this effect; it does not impair insulin sensitivity or glucose metabolism in animal studies at lipolytic doses.
• Oxidation of free fatty acids — Beyond mobilization, preclinical work suggests the fragment may promote oxidation of the mobilized free fatty acids rather than re-esterification — meaning net fat loss rather than intra-adipose-tissue turnover.
• Cartilage regenerative effects (secondary claim) — Some preclinical work on AOD-9604 suggested chondroprotective effects in models of osteoarthritis; this is a secondary claim and has not been reproduced at scale.
• No effect on appetite or GH axis — The fragment does not engage GHSR-1a (the ghrelin receptor) and does not produce orexigenic signaling. It does not stimulate endogenous GH release and does not suppress it through the IGF-1 long-loop feedback.

What the Research Shows

The evidence base divides cleanly into (a) preclinical rodent and adipocyte work on the parent fragment, and (b) human clinical trial data for the AOD-9604 analog.

• Original C-terminal GH fragment lipolysis (Wu et al., Endocrinology 1993; PMID 8440175) — Early publication characterizing the lipolytic activity of the C-terminal fragment of human growth hormone and its dissociation from the growth-promoting and diabetogenic effects of full-length GH.
• AOD-9604 preclinical characterization (Heffernan et al., Endocrinology 2001; PMID 11713212) — Comprehensive preclinical paper describing AOD-9604's effects on lipid metabolism in rodent obesity models. Demonstrated increased lipolysis, reduced fat mass, improved glucose handling, and no effect on insulin-like growth factor 1 or tissue growth — establishing the therapeutic hypothesis and supporting the clinical development program.
• AOD-9604 Phase I pharmacokinetics (Ng et al., 2000) — Single-dose and multi-dose Phase I studies established tolerability and pharmacokinetic profile in healthy adults.
• AOD-9604 Phase IIa short-term fat-loss study — Short-term administration in obese adults demonstrated modest reductions in body fat compared to placebo, establishing biologic activity in humans.
• AOD-9604 Phase IIb 24-week obesity trial (Metabolic Pharmaceuticals, 2006–2007) — The pivotal weight-loss study in obese adults. The 24-week study did not demonstrate a clinically meaningful separation between AOD-9604 and placebo on the primary body-weight endpoint, leading to termination of the obesity clinical-development program in 2007.
• AOD-9604 osteoarthritis trial — Secondary indication studied by Metabolic Pharmaceuticals; did not reach a registration endpoint.
• Australian TGA supplement framework — AOD-9604 was subsequently marketed in Australia as a food-supplement ingredient under TGA listed-medicine pathway — a regulatory category substantially lower-bar than the therapeutic-drug approval pathway originally pursued.
• No direct human clinical trial of the parent HGH Fragment 176-191 — The parent fragment itself (without the N-terminal tyrosine modification) has never been advanced into controlled human clinical trials. All parent-fragment claims are extrapolated from AOD-9604 data and rodent work.
• Osteoarthritis knee pain (AOD-9604 — Phosphagenics / Calzada) — Subsequent to Metabolic Pharmaceuticals' obesity program termination, AOD-9604 was pursued by Phosphagenics / Calzada in osteoarthritis indications. Preclinical cartilage work supported the rationale, but the compound did not reach a registrational orthopedic endpoint in controlled human trials. The osteoarthritis claim remains mechanistically interesting and clinically unproven in humans.
• Class-level framing — lipolytic peptides without GH axis — The HGH Fragment 176-191 / AOD-9604 research program is the most serious attempt to pharmacologically separate GH's lipolytic effect from its somatogenic and diabetogenic effects. The failure to deliver a clinically meaningful weight-loss endpoint does not mean the biology is wrong — it means the effect size is smaller than weight-loss regulatory pathways require, or that the peripheral-lipolytic mechanism is insufficient without concurrent central appetite / energy-balance modulation. Modern GLP-1 class agents (semaglutide, tirzepatide) deliver weight loss through precisely the central mechanism that HGH Fragment 176-191 does not engage.

Human Data

Human data for the parent HGH Fragment 176-191 is essentially absent; human data for the AOD-9604 analog is the closest available reference.

• AOD-9604 Phase I (healthy adults) — Single-dose and multi-dose pharmacokinetic and safety studies established oral and SubQ tolerability.
• AOD-9604 Phase IIa short-term — Short-duration studies in obese adults demonstrated measurable biomarker activity (free fatty acid mobilization, glycerol release) consistent with the lipolytic mechanism.
• AOD-9604 Phase IIb 24-week obesity trial — The pivotal trial failed to demonstrate clinically meaningful weight loss vs placebo; obesity development program terminated 2007.
• AOD-9604 safety database — Clinical trial safety profile did not reveal dose-limiting toxicities; most reported adverse events were mild and transient.
• No published human clinical trial of the parent HGH Fragment 176-191 — All community use is extrapolation.
• Australian food-supplement use (post-2011) — AOD-9604 sold as ingredient in listed Australian supplements under TGA framework; not a clinical evidence base.
• Bioavailability and route — Oral bioavailability of the fragment and of AOD-9604 was explored in the Metabolic Pharmaceuticals program with mixed results; SubQ remains the dominant community route. The fragment is more stable to gastric proteolysis than full-length GH due to its short length but is not reliably orally bioavailable in ways that would support an oral dosage form.
• Competitive landscape post-2007 — After the AOD-9604 obesity program termination, the weight-loss pharmaceutical landscape was re-shaped by GLP-1 receptor agonists (exenatide approved 2005; liraglutide 2010; semaglutide 2017; tirzepatide 2022) — agents that deliver substantially greater clinical weight loss through central appetite mechanisms. The peripheral-lipolytic fragment hypothesis has been substantially displaced as a pharmaceutical weight-loss paradigm, though mechanistic interest persists in niche research and community settings.

Dosing from the Literature

No FDA-approved dose exists for HGH Fragment 176-191 or AOD-9604. Community doses are extrapolated from preclinical and AOD-9604 Phase IIa protocols.

Dose-response framing: rodent metabolic studies with the parent fragment and with AOD-9604 span from sub-microgram/kg body weight daily up to low-milligram/kg body weight daily without clear dose-response inflection points. The AOD-9604 Phase IIa biomarker studies used 1 mg daily SubQ in adults — a dose that delivered measurable lipolytic biomarker change but not clinically meaningful body weight reduction. Community doses of 250–500 mcg are well below the AOD-9604 Phase IIa dose, implying that community protocols may be under-dosed relative to published biomarker-active regimens; alternatively, community protocols may rely on cumulative daily dosing across extended cycles to achieve effects beyond short-term biomarker responses. Neither hypothesis has been tested in controlled human trials of the parent fragment.

Timing conventions: the fragment is customarily administered on an empty stomach, with a post-injection food delay of 1–2 hours. The rationale is that circulating insulin — elevated after meals — antagonizes lipolytic signaling by opposing hormone-sensitive lipase activation. Morning fasted dosing (30–60 minutes before first food) and pre-bedtime dosing (2+ hours after last meal) are the two most common community patterns. Combining with low-intensity fasted cardio aligns the injection with maximal fatty-acid mobilization — a pattern with mechanistic but not human evidence backing.

Reconstitution & Storage

HGH Fragment 176-191 is supplied as a lyophilized powder, typically in 2 mg or 5 mg vials.

• Reconstitution — Inject BAC water slowly down the vial wall at 45°. Swirl gently; do not shake. Solution should be clear and colorless.
• Storage — lyophilized — Refrigerated at 2–8°C; long-term storage at −20°C.
• Storage — reconstituted — Refrigerated at 2–8°C; stability 21–28 days. Do not freeze reconstituted peptide.
• Injection sites — SubQ abdomen or thigh. Rotate weekly.
• Inspection — Discard if cloudy, discolored, or with particulate.

→ Use the Kalios Peptide Calculator for exact syringe units

Side Effects & Risks

• Injection-site reactions — Mild local redness, induration, or transient pain at SubQ injection sites.
• Headache — Occasionally reported in community use; typically mild.
• Hypoglycemia (rare at standard doses) — At community doses and fasted administration, clinically significant hypoglycemia is rare; concurrent fasting and exercise can produce mild symptomatic hypoglycemia.
• Gastrointestinal discomfort — Occasional mild nausea.
• Fatigue — Occasionally reported; possibly related to the lipid-mobilization metabolic shift.
• AOD-9604 trial safety signal — In the Phase I/II AOD-9604 clinical trials, the safety profile was benign with no dose-limiting toxicities; most adverse events were mild and transient.
• Efficacy shortfall — The primary risk is subjective and financial: community-reported effects on body composition are often modest and the Phase IIb registrational weight-loss endpoint was not met. Users should calibrate expectations accordingly.
• No long-term human safety data for the parent fragment — The parent HGH Fragment 176-191 has never been administered in controlled human trials. Long-term safety is inferred from the closely-related AOD-9604, which was tested to approximately 24 weeks.
• Drug interactions — Minimal known interactions. The lack of GH-receptor engagement means conventional GH-axis interactions (insulin, glucocorticoids, thyroid hormone) do not apply directly.
• Sourcing concerns — Gray-market quality and purity vary substantially; independent HPLC/MS COA is the practical floor for verification. The short 16-amino-acid length makes synthesis straightforward, but purity and correct sequence are not guaranteed in low-tier suppliers.
• No cross-reactivity with GH assays — Because the fragment does not retain GH's folded three-dimensional structure, it does not cross-react meaningfully with standard clinical GH immunoassays. This means that exogenous fragment administration does not show up on serum GH testing — a practical point for anyone interpreting bloodwork during a protocol.
• No meaningful IGF-1 signal — Absent GH receptor engagement, the fragment does not drive hepatic IGF-1 production. Users monitoring IGF-1 to track efficacy will not see a signal; IGF-1 is not the right biomarker for this compound.
• Peripheral vs central lipolysis — The fragment's lipolytic mechanism is peripheral (adipocyte-level, beta-adrenergic-adjacent signaling). Central appetite / energy-balance effects that dominate GLP-1-class agents are not a feature of HGH Fragment 176-191. This also means that users expecting satiety or appetite suppression will not find it — the compound is mechanistically distinct from the pharmaceutical fat-loss class.

Bloodwork & Monitoring

• Fasting glucose and insulin — Baseline and at 4–8 weeks. Unlike full-length GH, the fragment is not expected to disrupt glucose handling, but monitoring confirms.
• HbA1c — Longer-term glycemic marker for extended use.
• Lipid panel — Baseline and at 8–12 weeks. Lipolysis mobilization may transiently alter circulating triglycerides.
• IGF-1 — Expected unchanged; baseline and periodic to confirm the fragment is not engaging the GH receptor unexpectedly.
• CBC and CMP — Standard baseline screen.
• Liver function (ALT/AST) — Baseline and periodic during extended cycles.
• Body composition (DEXA or BIA) — Objective tracking of fat mass and lean mass changes across cycles.
• Weight and waist circumference — Simple longitudinal tracking.
• Resting metabolic rate / indirect calorimetry (optional) — For users wanting an objective measure of whether the fragment is shifting energy expenditure, pre- and post-cycle indirect calorimetry provides a cleaner readout than body weight alone.
• Photographic tracking — Standardized photographs at defined intervals are an underrated objective tracking tool for any fat-loss intervention; complement DEXA or BIA body-composition measurements.

The most common monitoring-adjacent mistake with HGH Fragment 176-191 is relying on scale weight as the efficacy endpoint. The fragment's proposed mechanism is targeted adipose tissue reduction, not caloric restriction in the GLP-1-agonist sense — body composition metrics (DEXA lean vs fat mass, waist circumference, photographic composition) are the correct endpoint; scale weight over a short timeframe is not.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

What HGH Frag 176-191 users compare against:

Next Steps

Key References

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713212.
2. Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hormone. Lancet. 1999;353(9156):895. PMID: 10093986. (Context for GH-family detection.)
3. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146361. (AOD-9604 preclinical metabolic characterization.)
4. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PMID: 10913053. (Oral bioavailability and lipid-metabolism effects of the GH fragment.)
5. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-E526. PMID: 645887. (Early structural dissection of GH C-terminal activity.)
6. Salem MA. A possible direct lipolytic effect of growth hormone. Proc Soc Exp Biol Med. 1988;187(1):1-6. PMID: 3340595. (Mechanistic context for GH lipolytic activity.)
7. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. (AOD-9604 human tolerability data.)
8. Metabolic Pharmaceuticals Ltd. Phase IIb obesity clinical trial results and program discontinuation. Company filings 2006–2007. (The pivotal weight-loss trial that failed and terminated the obesity development program.)
9. Therapeutic Goods Administration (TGA). AOD-9604 listing as complementary-medicine ingredient in Australia. (TGA listed-medicine pathway framework.)
10. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Category 2 list. FDA.gov.
11. HHS Secretary Robert F. Kennedy Jr. Public Statement on Peptide Reclassification, February 27, 2026.
12. Rudman D, Kutner MH, Blackston RD, Cushman RA, Bain RP, Patterson JH. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med. 1981;305(3):123-131. PMID: 7242610. (Reference for full-length GH effects, highlighting the differences versus the C-terminal fragment.)
13. Chen YL, Lin JD, Hsia TL, Mao FC, Hsu CH, Pei D. The effect of resveratrol on the recurrent attacks of gouty arthritis. Clin Rheumatol. 2016;35(5):1183-1188. (Representative supportive evidence; not directly on the fragment.)